Dermatologists routinely use dermoscopy to improve diagnostic accuracy of skin cancers. Much less is known about its use among other physicians who routinely examine the skin, such as family physicians, internists and plastic surgeons.
indicating that PCPs can effectively use the dermascope to increase their sensitivity of diagnosing malignant skin lesion with little or no decrease in specificity [17] [18] [19] . For instance, Argenziano et al reported statistically significant differences in sensitivity between dermoscopy and visual examination (79.2% vs 54.1% respectively); 23 malignant skin tumors were missed using visual examination and only 6 using dermoscopy [17] . In another study, dermoscopy significantly increased the PCP's ability to detect melanoma from dermoscopic images; sensitivity increased from 54.6% to 75.9% [18] . Using within-lesion controls, Menzies et al asked participants to rate suspicious lesions and provide management options (e.g., referral, biopsy, etc.) using visual inspection and then to repeat the rating with the aid of a dermascope [19] .
There was a 63.5% reduction in the number of benign lesions requiring excision or referral from use of the dermoscopic intervention and sensitivity of diagnosis almost doubled. A recent study of French PCPs provides additional evidence supporting use of the dermascope for melanoma screening [20] . These studies suggest dermoscopy can improve the PCP's diagnostic accuracy for skin cancer.
Another group that may benefit from using the dermascope is plastic surgeons. Interest among this group of physicians is increasing as demonstrated by a recent study conducted among plastic surgeons attending the first Dermoscopy for Plastic Surgeons conference [21] . Participants were asked to mark skin lesions as certainly benign (leave), probably benign (excise) and malignant (excise) based on a clinical picture before and after a one-day dermoscopy training course [21] . After the training course, and with the addition of the dermoscopic images, the sensitivity of accurately diagnosing a malignant lesion increased from 56% to 64% and specificity increased from 44% to 64%. Dermoscopy also resulted in a near doubling in the number of correctly diagnosed benign lesions. Expanding use of the dermascope among plastic surgeons may yield additional benefits in the diagnosis and treatment of skin cancer and may also lead to additional uses for the dermascope.
In spite of this strong evidence supporting the dermascope as an important diagnostic tool, little is known about use of the dermascope among US based physicians. In response to this need, we conducted a study to: (1) document the use of dermoscopy in a sample of US physicians; (2) examine physician and practice characteristics associated with ever having used a dermascope and intentions to use a dermascope; and (3) examine possible barriers that might hamper its use.
Introduction
Skin cancer is the most common cancer in the United States (US) [1] . Over the past three decades, there have been more cases of skin cancer reported than all other cancers combined [2, 3] . Skin cancer poses a substantial and increasing economic burden on the US health care system [4] . Between 2007 and 2011, the average annual cost for treating skin cancer increased by 126.2% compared to a 25.1% increase for all other cancers [4] . Although non-melanoma skin cancers are more prevalent, melanoma is far more deadly [5] . During the past three decades, there has been 20% to 60% decrease in mortality rates for cancers of the cervix, colon, prostate and breast while mortality from melanoma has increased [6, 7] . Early detection is key to achieving more positive treatment outcomes [8] .
Because many patients are seen first by primary care physicians (PCPs), these doctors are poised to play a critical role in early detection of skin cancers. The most common way that many PCPs screen for skin cancer is through visual inspection, which is not highly sensitive [9] . Among PCPs the sensitivity of visual inspection ranges from 37.5% to 60.9% [9] . Thus, reliance on visual inspection alone may not be the optimal strategy for early detection of skin cancers. Adding relatively inexpensive, but highly sensitive and specific non-invasive technology, such as the dermascope, may enhance the effectiveness of visual exams for detecting early stage skin cancers.
Dermoscopy is a non-invasive in vivo technique that allows visualization of subsurface structures of the skin that are not visible with the naked eye. Several meta-analyses provide strong evidence indicating that dermoscopy improves accuracy in diagnosing skin cancer [10] [11] [12] . In a 2008 metaanalysis, the odds of melanoma detection by dermoscopy was 15.6 times higher than by naked-eye examination (CI = 2.9-83.7, p = .016), and the sensitivity rate was 90% compared to 71% for naked-eye examination with no significant changes in specificity [10] . In a more recent study, dermoscopy resulted in 42% fewer excisions compared to naked-eye examination and had a 21% increase in specificity [13] .
Despite the benefits, the diagnostic accuracy of the dermascope is contingent on the skill of the user and the cancerous lesions having typical features [14] . Notwithstanding, dermoscopy is routinely used among dermatologists in many countries. For instance, approximately 95% of dermatologist in France, 98% of those in Australia, and 98.5% of those in the UK use dermoscopy in their clinical practice [15] . In contrast, use of dermoscopy among US dermatologists is much lower. In 2009, 48% of the 3,238 US dermatologists surveyed reported using dermoscopy in their practice [16] . Efforts to promote the use of the dermascope among US dermatologists are warranted.
Because dermascopes are relatively inexpensive and easy to use with minimal training, they can be readily integrated into routine primary care [17] . There is emerging evidence [22] . The sample size for the logistic regression on "ever used a dermascope" (which we refer to as Model 1) was 1,332 and the sample size for the logistic regression on "intentions to use a dermascope" (which we refer to as Model 2) was 1,168. The reduced sample size for Model 2 was due to missing data on the dependent variable, which occurred at the early stages of data collection. As soon as we realized that some participants were skipping the intention item because it was partially hidden by the clipboard, we remedied the situation.
Results
Sample characteristics are described in Table 1 . Our sample was primarily white (77.1%), males (65.3%), trained as DO's (62%), and identified as family physicians (48.4%). Fifty-four e-mail, etc.) to complete a brief cross-sectional survey. We recruited at nine national and international conferences that primarily targeted PCPs and others most likely to use dermoscopy. We purposefully excluded recruiting at conferences targeting dermatologists. To reduce cost, we focused on conferences held in cities (e.g., Tampa We approached potential participants, briefly described the study and ascertained whether or not they were eligible.
To those eligible and willing to participate, we gave a clipboard with the survey and an explanatory cover letter stating that participation is voluntary, that they would not receive an incentive, and that by completing the survey they were consenting to be in the study. Eighty-six percent of participants were recruited face-to-face and the majority of those eligible agreed to participate. We used SurveyMonkey ® to create an electronic version of the cover letter and questionnaire which we distributed via personal e-mails and professional list servers. Eligible and willing participants clicked on the link provided and were redirected to a secure website to complete the survey. We entered paper surveys into SPSS ® and merged the file with the data collected online.
Because we found no standardized instrument to measure dermoscopy use in the published literature, we selected specific items from past surveys directly relevant to our study and developed new items to assess domains of interest. We pilot tested the newly developed survey on ten respondents to assess comprehension and readability. We revised select items to improve comprehension and omitted items that were US physicians. Thus, the low rates of dermoscopy use in our study may be partially explained by the absence of practice guidelines. Reimbursement rates may also be a limiting factor to its use in the US since no additional reimbursement is provided, as is true for otoscopy or stethoscopy [25] . This is in direct contrast to practices in other countries such as Australia, where dermoscopy has been reimbursable since 1987 [26] . Given skin cancer's burden on the health care system and the benefits of early detection, promoting the use of dermoscopy to US physicians, who routinely examine pigmented skin lesions, is warranted.
It is interesting to note that cost and reimbursement were two of the three most frequently cited barriers to incorporating the dermascope into routine practice. Although not specifically stated, the other barrier, time and training requirements, also has fiscal elements. In the current managed care environ- The results of the two logistic regressions are reported in Table 3 . Graduating medical school more recently, being a family physician, seeing a higher number of cancer patients 
Discussion
Although there is widespread use of dermoscopy among physicians in other countries, our study indicates low use among US physicians. Treatment guidelines from other countries recommend use of dermoscopy to improve diagnostic accuracy [23, 24] . Similar recommendations have yet to be issued for large proportion of participants practiced in the Southeast since we primarily recruited at conferences located in this region of the country. Our findings can only be generalized to physicians attending these conferences. Our data collection method was self-report, which has some limitations [32] .
However given that we were not collecting sensitive data, the tendency towards providing socially desirable responses in self-report data was minimized. Because we expected that many participants would have little knowledge of the dermascope, we provided a brief description of its properties (that it was relatively inexpensive, easy to use and more effective for screening than naked-eye examinations) as a preamble to the intention items. Although this positive description might have prompted some participants to respond more favorably, almost half did not suggesting that the effect was attenuated.
Last, because participants completed the survey without direct oversight from the researchers, there were some skip pattern errors and missed responses.
In summary, our study represents an initial step in understanding use of dermoscopy among US based physicians.
Despite the strong evidence supporting use of dermoscopy to enhance diagnostic accuracy primarily for melanoma, the low levels of use among US-based physicians is concerning, particularly in light of the morbidity, mortality and health care cost of melanomas, especially those detected later in their disease course. Although the evidence supporting routine population-based screening for skin cancer is equivocal, promoting routine dermoscopic screening of patients at high risk may be beneficial [33] . Efforts to increase dermoscopy use among physicians routinely examining high-risk patients are needed.
